Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk dominates the obesity and diabetes markets thanks to its long list of hit medications. Wegovy was just approved for an expanded indication, and Novo Nordisk's Amycretin could be its next blockbuster drug.

With Shares Trading Near All-Time Highs, Is Now the Time to Take Profits in Novo Nordisk?

Germany's public health insurance scheme can cover certain patients with a risk of heart disease or strokes to take the weight-loss Wegovy drug, a big boost for Novo Nordisk's efforts to convince governments of its wider medical benefits.

Germany's health insurance could cover Wegovy for strokes, heart conditions, agency says

Amgen

Intellia Therapeutics

When it comes to risk vs. reward in the stock market, the biotech sector has one of the highest potential payoffs.

Hot Stocks: The 3 Best Opportunities for Investing in Biotech

Eli Lilly

Older adults may now get Medicare coverage for the popular obesity drug Wegovy, so long as they're using it to cut their risk of serious heart problems and not for weight loss alone, according to new guidance from the Centers for Medicare and Medicaid Services.

Medicare allows coverage of Wegovy for heart patients

Novo Nordisk and Eli Lilly stocks edged higher Thursday after Medicare said it could pay for weight-loss drugs for some members.

Medicare Will Cover Weight-Loss Drugs — For Some. Here's What It Means For Novo, Lilly.

Novo Nordisk (NYSE:NVO) is at risk of missing first-quarter consensus estimates, due in part to the slow uptake of its flagship Wegovy drug in the US, Jefferies analysts have warned. As per the bank, sales over the first quarter will likely sit at 59.1 billion Danish Krone, 9% lower than consensus estimates of 64.7 billion.

Novo Nordisk sales face hit on slow US uptake of weight loss drug - analysts

Danish drugmaker Novo Nordisk on Thursday said its once-weekly basal insulin icodec for treatment of diabetes in adults had received a recommendation for marketing authorisation from the European Medicines Agency's human medicines committee.

Novo Nordisk's once-weekly basal insulin icodec recommended for marketing approval in Europe

Bagsværd, Denmark, 21 March 2024 - Today, Novo Nordisk A/S held its Annual General Meeting. At the Annual General Meeting, Helge Lund, chair of the Board of Directors communicated: “We are very pleased with the performance in 2023 which was an exceptional year of innovation, growth, value creation and impact for Novo Nordisk.

Resolutions from the Annual General Meeting of Novo Nordisk A/S

Broadcom

eBay

Lowe's

Lyft

Spotify

Toll Brothers

What a difference a Fed meeting can make. Stocks are again ripping higher after the U.S. Federal Reserve signalled that it still expects to deliver three interest rate cuts this year.

7 Stocks That Are Creating a Buzz on Wall Street

Novo Nordisk recently released trial results for its weight loss pill amycretin. In an early-stage trial, the drug performed better than Wegovy.

Novo Nordisk's New Weight Loss Drug Could Be Better Than Ozempic and Wegovy

Germany's health ministry said that no large volumes of diabetes drug Ozempic are being exported out of the country, quashing a suggestion by the nation's drugs regulator that outbound trade in the drug, coveted for its weight-loss effect, may have to be banned.

German health ministry says Ozempic exports are not a concern

CRISPR Therapeutics

Vertex Pharmaceuticals

Biopharma stocks have been among the most popular and well-performing stocks this year. With recent trends in weight loss drugs and clinical advancements in treating illnesses, this market is set for significant advances this year.

3 Biopharma Stocks Predicted to Soar in Q2 2024

Novo Nordisk's shares have benefited from some recent positive developments. The delay in the approval of donanemab has held back Eli Lilly's valuation.

Will Novo Nordisk Overtake Eli Lilly as the Most Valuable Healthcare Stock?

Eli Lilly's Mounjaro and Novo Nordisk's Ozempic and Wegovy are headliners in the expected boom in GLP-1 weight-loss drugs. But investors are making even more money on tangential players.

Feisty Rivals Take On Eli Lilly, Novo Nordisk On Weight Loss

Weightwatchers International Inc.

A new medical study is raising concerns over whether intermittent fasting, a weight-loss method that's gained attention in recent years, could pose heart-health risks.

A new study cites the health risks of intermittent fasting. Could it lift Ozempic sales?

Novo Nordisk is enjoying stunning growth thanks to its breakthroughs in diabetes and obesity. The company is looking to augment its obesity care line with an oral drug called amycretin.

Is Novo Nordisk on the Verge of Another Blockbuster Drug?

Novo Nordisk and Eli Lilly have witnessed staggering success with their diabetes and obesity treatments. Both companies have been testing the main compounds in their respective medications for additional indications -- particularly in heart disease.

Did Novo Nordisk Just Get a Jump on Eli Lilly?

Madrigal Pharmaceuticals

Last week's FDA approval of Rezdiffra in treating NASH is a huge milestone for Madrigal. Lilly and Novo Nordisk look much more impressive than Madrigal in most ways.

Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?

The Novo Nordisk Foundation chooses Eviden to build “Gefion” in Denmark, one of the world's most powerful AI supercomputers

Novo Nordisk (NVO) concluded the recent trading session at $132.89, signifying a +0.39% move from its prior day's close.

Novo Nordisk (NVO) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Roche Holding AG

Novo Nordisk's Wegovy represents a significant advancement in obesity treatment, demonstrating a more profound weight-loss effect compared to its predecessor, Saxenda. Eli Lilly's entry with Zepbound, targeting both GLP-1 and GIP, signifies a competitive market landscape, potentially outperforming Wegovy in efficacy. The race to redefine obesity treatment is heating up, with several other pharmaceutical companies developing GLP-1 agonists and exploring alternative targets.

Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront

The Novo Nordisk Foundation, top shareholder of Danish obesity drugmaker Novo Nordisk , plans to give a larger portion of its social, scientific and humanitarian grants outside of Denmark, a foundation spokesperson said on Monday.

Novo Nordisk foundation to place more grants outside Denmark

Some health plans and employers are still reluctant to cover Wegovy due to its hefty price tag, which they say could significantly strain their budgets.

Weight loss drug Wegovy is now approved for heart health — but that won't mean broad insurance coverage just yet

Novo Nordisk is a leader and innovator in the diabetes drug market. The pharmaceutical company is making strides in obesity care, too.

Novo Nordisk Isn't in The "Magnificent Seven," but Here's Why I Think It Should Be

Novo Nordisk recently presented encouraging phase 1 results for an oral obesity treatment candidate. The company has many more promising programs in its early-stage pipeline.

News for Novo Nordisk Stock (NVO)